EoE KIDS: Higher Exposure Dupilumab Improves Histologic, Endoscopic Outcomes
Higher exposure dupilumab significantly improved histologic and endoscopic outcomes in children with EoE aged 1 to <12 years.
Source: hcplive.com
Stay updated with breaking news from Improves Histologic. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Higher exposure dupilumab significantly improved histologic and endoscopic outcomes in children with EoE aged 1 to <12 years.